Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesHematology/OncologyBaylor Scott & White Aucatzyl Prior Auth | OpenPay…
    Ask Trek AI about this page
    CurrentBaylor Scott & White Health PlanPolicy 315

    Obecabtagene autoleucel (Aucatzyl)

    Customize your policy alerts

    Sign up for Baylor Scott & White Health Plan Policy 315 alerts

    Get alerted when Policy 315 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and medical-necessity review for obecabtagene autoleucel used to treat adult members with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. It applies across lines of business unless otherwise specified by the member's benefit plan, with separate Medicare and Medicaid coverage guidance noted.

    Policy Summary
    PayerBaylor Scott & White Health Plan
    PolicyObecabtagene autoleucel (Aucatzyl)
    Policy CodePolicy 315
    Change TypeMaterial revision
    Effective DateSep 1, 2026
    Last ReviewJul 23, 2026
    Next Review DateJul 23, 2027
    Key ActionSubmit prior authorization requests demonstrating that all medical-necessity criteria are met.
    SourceLink
    POLICY UPDATE CHANGES

    Added exclusion of members with prior treatment using CAR-T cell immunotherapy.

    Updated the applicable HCPCS code for obecabtagene autoleucel.

    Adult R/R ALLCovered population
    ≥18Minimum age
    ECOG 0–1Performance status
    1 courseLifetime course limit

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    410 × 10^6Total dose
    75% CRS; 64% neurologicReported toxicities

    Medical Necessity and Exclusions

    Course limitation

    One course is medically necessary per lifetime.

    Lifetime course limitation: Obecabtagene autoleucel is administered as one split-dosed course per lifetime. Repeat courses are considered experimental and investigational because the effectiveness of repeat treatment has not been established.1 course per lifetime

    The policy-supported course is split into two doses.

    Coverage is not available when the member has received tafasitamab or loncastuximab; has Burkitt leukemia/lymphoma or chronic myelogenous leukemia in lymphoid blast crisis; has clinically relevant central nervous system pathology, CNS-3 disease, or CNS-2 disease with neurologic changes; has an active or uncontrolled infection requiring systemic antimicrobials; has active or latent hepatitis B, active hepatitis C, HIV, HTLV-1, HTLV-2, or a positive syphilis test; has active significant acute graft-versus-host disease or moderate/severe chronic graft-versus-host disease requiring systemic treatment; experienced grade 3 or higher neurotoxicity following blinatumomab; underwent allogeneic HSCT within 3 months before planned therapy; is pregnant; or previously received CAR-T cell immunotherapy.

    The member must not have received more than 10 mg daily of prednisone or its equivalent within 7 days before leukapheresis or within 72 hours before obecabtagene autoleucel. Coverage also requires no immunosuppressive medications, donor lymphocyte infusion, or graft-versus-host disease medication within 2 weeks before leukapheresis, with additional required medication-free intervals for antineoplastic chemotherapy, tyrosine kinase inhibitors, alemtuzumab, clofarabine or cladribine, live vaccines, and intrathecal antineoplastic chemotherapy. Specifically, these include no antineoplastic chemotherapy within 1 week before leukapheresis or preconditioning chemotherapy; no tyrosine kinase inhibitor within 72 hours before preconditioning chemotherapy; no alemtuzumab within 6 months before leukapheresis; no clofarabine or cladribine within 3 months before leukapheresis; no live vaccine within 4 weeks before leukapheresis; and no intrathecal antineoplastic chemotherapy within 2 weeks before starting preconditioning chemotherapy.

    BSWHP considers one split-dosed course per lifetime medically necessary. Repeat courses after that course are considered experimental and investigational because the effectiveness of repeat treatment has not been established.

    Treatment of indications other than relapsed or refractory B-cell precursor acute lymphoblastic leukemia that meet the policy criteria is considered experimental and investigational because the effectiveness of obecabtagene autoleucel for other indications has not been established.

    Covered Coding and Clinical Parameters

    Covered CPT CodesCPTCovered
    38228Chimeric antigen receptor T-cell (CAR-T) therapy; CAR-T cell administration, autologous.
    Covered HCPCS CodesHCPCSCovered
    Q2058Obecabtagene autoleucel, 10 up to 400 million cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per infusion.
    Covered ICD-10 CodesICD-10Covered
    C91.00Acute lymphoblastic leukemia not having achieved remission.
    C91.02Acute lymphoblastic leukemia, in relapse.
    Age
    Minimum ageMember must be at least 18 years old.
    PopulationAdult members with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
    Coverage applicationThe age requirement applies to treatment with obecabtagene autoleucel.
    ECOG Performance Status
    Required scoreECOG performance status must be 0 or 1.
    AssessmentThe member’s Eastern Cooperative Oncology Group performance status must be documented.

    Authorization and Documentation Requirements

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required. Requests must demonstrate that all applicable medical-necessity criteria are met and should follow Medicare guidance, including NCD 110.24, or Texas Medicaid requirements in the TMHP Provider Procedures Manual, including Texas Mandate HB154 when applicable.

    • Submit records supporting the requested use of obecabtagene autoleucel (Aucatzyl) for a qualifying indication.
    Note

    Dual Clinical Review

    Every request is reviewed by both a clinical pharmacist and a medical director before a coverage determination is made.

    Therapy Overview

    Obecabtagene autoleucel is an autologous CD19-directed CAR-T cell therapy for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. The therapy uses the member’s genetically modified T cells to target CD19-positive disease and is administered following lymphodepleting chemotherapy.

    Key Terms

    CAR-T Cells
    Cell typeCAR-T cells are genetically engineered T cells manufactured from lymphocytes collected from a patient or donor.
    Extracellular componentThe hybrid receptor includes an extracellular single-chain antibody fragment.
    Transmembrane componentThe hybrid receptor includes a transmembrane domain.
    Intracellular componentThe hybrid receptor includes at least one intracellular signaling domain.
    TargetThe receptor directs an immune response against tumor antigens such as CD19.
    Split-Dosed Therapy
    Total recommended dose

    Treatment Setting

    Salvage — Philadelphia chromosome-negative disease

    Salvage therapy is covered when the applicable relapsed or refractory disease-history criterion is met.

    Relapsed/refractory disease treatment history

    • Primary refractory B-cell precursor ALL, with no complete response after two cycles of induction chemotherapy.
    • First relapse following a remission lasting 12 months or less.First-relapse remission ≤12 months
    • Relapsed or refractory B-cell precursor ALL after two or more lines of systemic therapy.
    • Relapsed or refractory B-cell precursor ALL at least 3 months after allogeneic HSCT.At least 3 months after allogeneic HSCT

    Disease and Biomarker Status

    CD19
    Required expressionTumor expression of CD19 must be documented.
    Prior blinatumomabIf the member previously received blinatumomab, a repeat biopsy is required.
    Repeat biopsy resultThe repeat biopsy must indicate CD19-positive disease.
    Treatment relevanceCD19 expression is required for covered obecabtagene autoleucel treatment.
    Philadelphia Chromosome (Ph) Status
    Qualifying statusThe member must have Philadelphia chromosome-negative or Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukemia.

    Covered Treatment Components

    RegimenClinical contextCoverage
    Obecabtagene autoleucel monotherapyAdults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia meeting policy criteria; preceded by fludarabine and cyclophosphamide lymphodepleting chemotherapy. Total recommended dose: 410 × 10^6 CD19 CAR-positive viable T cells, administered as a split-dose infusion on Day 1 and Day 10 (±2 days), based on bone marrow blast assessment.Covered
    RegimenClinical contextCoverage
    Lymphodepleting chemotherapyRequired preparative therapy before obecabtagene autoleucel infusion; may include fludarabine and cyclophosphamide.Covered
    RegimenClinical contextCoverage
    Repeat obecabtagene autoleucel coursesRepeat treatment after one split-dosed course per lifetime.Experimental and investigational
    Policy Summary
    PayerBaylor Scott & White Health Plan
    PolicyObecabtagene autoleucel (Aucatzyl)
    Policy CodePolicy 315
    Change TypeMaterial revision
    Effective DateSep 1, 2026
    Last ReviewJul 23, 2026
    Next Review DateJul 23, 2027
    Key ActionSubmit prior authorization requests demonstrating that all medical-necessity criteria are met.
    SourceLink
    On This Page
    Medical Necessity and ExclusionsCovered Coding and Clinical ParametersAuthorization and Documentation RequirementsTherapy OverviewKey TermsTreatment SettingDisease and Biomarker StatusCovered Treatment Components
    Coverage applicationThe requirement applies to eligibility for obecabtagene autoleucel treatment.
    Primary Refractory Disease
    DefinitionPrimary refractory acute lymphoblastic leukemia is disease that has not achieved complete response after two cycles of induction chemotherapy.
    Response assessmentComplete response is assessed after induction chemotherapy.
    Disease categoryThis is one qualifying pathway for Philadelphia chromosome-negative B-cell precursor ALL.
    First Relapse Remission Duration
    Maximum remission durationFirst relapse must follow a remission lasting 12 months or less.
    Relapse pathwayThe criterion applies to first relapse of B-cell precursor acute lymphoblastic leukemia.
    Disease categoryThis is one qualifying pathway for Philadelphia chromosome-negative B-cell precursor ALL.
    Post-Allogeneic HSCT Relapse or Refractory Disease
    Minimum intervalRelapsed or refractory disease must occur at least 3 months after allogeneic stem cell transplantation.
    Transplant typeThe interval is measured from allogeneic hematopoietic stem cell transplantation.
    Disease pathwayThis is one qualifying pathway for relapsed or refractory B-cell precursor ALL.
    Recent Allogeneic HSCT
    Exclusion intervalAllogeneic stem cell transplantation must not have occurred within 3 months before planned obecabtagene autoleucel therapy.
    ProcedureThe exclusion concerns prior allogeneic stem cell transplantation.
    Timing referenceThe 3-month interval is measured before planned obecabtagene autoleucel treatment.
    Corticosteroid Exposure
    Prednisone-equivalent limitCorticosteroid exposure must not exceed 10 mg daily of prednisone or its equivalent.
    Before leukapheresisThe limit applies within 7 days before leukapheresis.
    Before infusionThe limit also applies within 72 hours before obecabtagene autoleucel infusion.
    Documentation Required

    Diagnosis and Relapse/Refractory Status

    Document that the member is at least 18 years old and has B-cell precursor acute lymphoblastic leukemia (ALL) with the applicable relapsed or refractory disease status. Medical records must support the diagnosis and the relevant Philadelphia chromosome status, treatment history, remission duration, relapse, refractory disease, transplantation history, or tyrosine kinase inhibitor history.

    • For Ph-negative disease, document primary refractory disease or qualifying relapse/refractory status.
    • For Ph-positive disease, document the applicable failed, intolerant, or contraindicated TKI therapy.
    Documentation Required

    Clinical Eligibility

    Submit documentation establishing clinical eligibility for treatment and the planned treatment approach. The member must have CD19-positive tumor expression, diagnosis by a hematologist or oncologist, and an ECOG performance status of 0 or 1.

    • Attest that treatment will occur at an authorized treatment center and as monotherapy.
    • Document apheresis eligibility, planned lymphodepleting chemotherapy, and dosing and frequency consistent with FDA labeling or NCCN guidelines.
    Documentation Required

    Exclusion Screening

    Screen the member for every exclusion before requesting authorization and document that none apply. The review must address excluded diseases and prior therapies, central nervous system and neurologic conditions, infections and positive infectious-disease tests, graft-versus-host disease, pregnancy, recent transplantation, prior CAR-T therapy, and prohibited medication exposures or treatment timing.

    • Review for Burkitt leukemia/lymphoma, chronic myelogenous leukemia in lymphoid blast crisis, prior tafasitamab or loncastuximab, and prior CAR-T immunotherapy.
    • Document absence of CNS-3 disease or CNS-2 disease with neurologic changes, clinically relevant CNS pathology, active or uncontrolled infection, specified viral or bacterial infections, significant graft-versus-host disease, and grade 3 or higher neurotoxicity after blinatumomab.
    • Verify pregnancy status, timing of allogeneic HSCT, and the required washout periods for corticosteroids, immunosuppressants, donor lymphocyte infusion, graft-versus-host disease drugs, chemotherapy, TKIs, alemtuzumab, clofarabine or cladribine, live vaccines, and intrathecal chemotherapy.
    Documentation Required

    Prior Blinatumomab

    When the member has received prior blinatumomab, submit repeat biopsy documentation demonstrating CD19-positive disease.

    Denial Risk

    Repeat Course

    Obecabtagene autoleucel is split-dosed. BSWHP considers one medically necessary split-dosed course per lifetime; repeat courses are experimental and investigational because effectiveness has not been established.

    • Flag any request for a second or subsequent course for experimental and investigational review.
    Denial Risk

    Other Indications

    Use of obecabtagene autoleucel outside the qualifying relapsed or refractory B-cell precursor ALL indications is experimental and investigational because effectiveness has not been established.

    • Confirm that the requested indication meets the policy's qualifying disease and treatment-status criteria.
    Denial Risk

    Disqualifying Conditions or Exposures

    Coverage may be denied when any disqualifying disease, condition, prior exposure, infection, graft-versus-host disease, neurologic condition, prohibited medication exposure, or required washout-period violation is present. Requests must document that all listed disqualifiers have been ruled out.

    • Disqualifiers include prior tafasitamab, loncastuximab, or CAR-T therapy; specified leukemia or lymphoma; CNS pathology or disease; active infection or specified positive infectious tests; significant graft-versus-host disease; pregnancy; recent HSCT; and grade 3 or higher post-blinatumomab neurotoxicity.
    • Disqualifying exposures include recent corticosteroids, immunosuppressants, donor lymphocyte infusion, graft-versus-host disease drugs, antineoplastic chemotherapy, TKIs, alemtuzumab, clofarabine or cladribine, live vaccines, or intrathecal antineoplastic chemotherapy outside the required intervals.
    410 × 10^6 CD19 chimeric antigen receptor-positive viable T cells.
    Day 1 administrationThe split-dose infusion begins on Day 1.
    Day 10 administrationThe remaining dose is administered on Day 10.
    Permitted intervalThe second dose may be administered within plus or minus 2 days of Day 10.
    Dose determinationThe split-dose schedule is based on bone marrow blast assessment.

    Salvage — Philadelphia chromosome-positive disease

    Salvage therapy is covered when the applicable TKI treatment-history criterion is met.

    TKI treatment failure, intolerance, or contraindication

    • Failed two lines of any tyrosine kinase inhibitor (TKI).
    • Failed one line of a second-generation TKI, such as bosutinib, dasatinib, or nilotinib.
    • Intolerant to TKI therapy.
    • Has a contraindication to TKI therapy.
    Ph-negative pathway
    Ph-negative disease qualifies through the specified primary refractory, relapse, or prior-treatment criteria.
    Ph-positive pathwayPh-positive disease qualifies through the specified tyrosine kinase inhibitor failure, intolerance, or contraindication criteria.